二甲双胍用于糖尿病预防:来自糖尿病预防计划/糖尿病预防计划结局研究的见解
本文综述糖尿病预防计划/糖尿病预防计划结局研究(DPP/DPPOS)的数据,聚焦二甲双胍用于糖尿病预防的长期血糖与心血管代谢效应及安全性。DPP为随机对照试验,纳入3234名高危成人,二甲双胍850mg每日两次在平均2.8年随访中较安慰剂降低糖尿病发生率31%,DPPOS显示随机化后10年和15年风险降低18%。
要点
- DPP中二甲双胍850mg每日两次较安慰剂降低糖尿病发生率31%,在更肥胖、空腹血糖更高或有妊娠期糖尿病史者中效果更大。
- DPPOS显示二甲双胍在随机化后10年和15年风险降低18%,且用于糖尿病预防估计可节省成本。
- 15年时未进展为糖尿病与微血管并发症风险降低28%相关,各治疗组间无差异。
核心结论
- 二甲双胍已被证明可预防或延迟糖尿病,可能成为应对日益增长的糖尿病流行的重要工具。
- DPP/DPPOS正在进行的长期随访正在评估二甲双胍在血糖异常早期启动对后期合并症(包括心血管疾病和癌症)的潜在作用。
研究设计与样本
- DPP(1996-2001)为随机对照试验,纳入3234名基线时糖尿病高危成人,分配至盲法安慰剂(n=1082)、二甲双胍850mg每日两次(n=1073)或强化生活方式干预(n=1079)。
- 盲法二甲双胍/安慰剂干预阶段因疗效显现提前约1年结束,主要结局在2.8年时报告。
- DPP结束时所有参与者接受生活方式教育,88%(n=2776)存活DPP队列继续在DPPOS中随访,原分配至二甲双胍者继续接受非盲法二甲双胍。
- DPP/DPPOS队列现已随访超过15年,前瞻性评估血糖、心血管代谢、卫生经济学和安全性结局。
主要发现
- 平均随访2.8年后,二甲双胍较安慰剂降低糖尿病发生率31%,在更肥胖、空腹血糖更高或有妊娠期糖尿病史者中效果更大。
- DPPOS显示二甲双胍在随机化后10年和15年风险降低18%。
- 二甲双胍用于糖尿病预防估计可节省成本。
- 15年时未进展为糖尿病与微血管并发症风险降低28%相关,各治疗组间无差异。
- 近期发现提示二甲双胍可能减少男性动脉粥样硬化发展。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The largest and longest clinical trial of metformin for the prevention of diabetes is the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study (DPP/DPPOS). In this review, we summarise data from the DPP/DPPOS, focusing on metformin for diabetes prevention, as well as its long-term glycaemic and cardiometabolic effects and safety in people at high-risk of developing diabetes. The DPP (1996-2001) was a RCT of 3234 adults who, at baseline, were at high-risk of developing diabetes. Participants were assigned to masked placebo (n = 1082) or metformin (n = 1073) 850 mg twice daily, or intensive lifestyle intervention (n = 1079). The masked metformin/placebo intervention phase ended approximately 1 year ahead of schedule because of demonstrated efficacy. Primary outcome was reported at 2.8 years. At the end of the DPP, all participants were offered lifestyle education and 88% (n = 2776) of the surviving DPP cohort continued follow-up in the DPPOS. Participants originally assigned to metformin continued to receive metformin, unmasked. The DPP/DPPOS cohort has now been followed for over 15 years with prospective assessment of glycaemic, cardiometabolic, health economic and safety outcomes. After an average follow-up of 2.8 years, metformin reduced the incidence of diabetes by 31% compared with placebo, with a greater effect in those who were more obese, had a higher fasting glucose or a history of gestational diabetes. The DPPOS addressed the longer-term effects of metformin, showing a risk reduction of 18% over 10 and 15 years post-randomisation. Metformin treatment for diabetes prevention was estimated to be cost-saving. At 15 years, lack of progression to diabetes was associated with a 28% lower risk of microvascular complications across treatment arms, a reduction that was no different among treatment groups. Recent findings suggest metformin may reduce atherosclerosis development in men. Originally used for the treatment of type 2 diabetes, metformin, now proven to prevent or delay diabetes, may serve as an important tool in battling the growing diabetes epidemic. Long-term follow-up, currently underway in the DPP/DPPOS, is now evaluating metformin's potential role, when started early in the spectrum of dysglycaemia, on later-stage comorbidities, including cardiovascular disease and cancer. TRIAL REGISTRATION: ClinicalTrials.gov NCT00038727 and NCT00004992.
引用
- Aroda VR, Knowler WC, Crandall JP, et al. Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia. 2017. PMID: 28770322. doi:10.1007/s00125-017-4361-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。